MESO — Mesoblast Limited

Summary of Mesoblast Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Mesoblast reported $17.2 million in revenue from cell therapy products for the fiscal year ending June 30, 2025, a significant increase of 191% year-over-year, largely driven by the launch of Ryoncil.
• Sales Breakdown: Ryoncil generated $13.2 million in gross sales and $11.3 million in net sales after a 14.6% gross-to-net adjustment.
• Expenses: Net operating cash spend was $50 million, consistent with the prior year, despite increased costs related to commercial team expansion and product launch.
• Cash Position: As of June 30, 2025, the company had $162 million in cash.

2. Strategic Updates and Business Highlights

• Product Launch: Ryoncil, the first FDA-approved mesenchymal stromal cell therapy, was launched in March 2025 for pediatric steroid-refractory acute graft-versus-host disease (GvHD). The company aims to onboard the top 45 transplant centers in the U.S. by the end of the quarter.
• Market Opportunities: The addressable market for Ryoncil is approximately $1 billion for pediatric GvHD, with potential expansions into adult GvHD ($3 billion market), inflammatory bowel disease (over $5 billion), chronic heart failure (over $10 billion), and chronic low back pain (over $10 billion).
• Clinical Trials: Mesoblast is preparing to initiate pivotal trials for Ryoncil in adults with GvHD and for inflammatory colitis. Additionally, they are enrolling a confirmatory Phase III trial for rexlemestrocel-L in chronic low back pain.

3. Forward Guidance and Outlook

• Sales Growth: The company expects continued sales growth as it builds infrastructure and expands coverage with payers. However, specific revenue guidance for future quarters was not provided.
• Trial Initiatives: The adult GvHD trial is expected to commence this quarter, and the company is working on trial designs for inflammatory bowel disease.
• Regulatory Pathway: Mesoblast is preparing for an accelerated approval filing for its heart failure product, Revascor, based on existing trial data.

4. Bad News, Challenges, or Points of Concern

• Increased Expenses: Selling, general, and administrative expenses rose to $39.3 million, reflecting the costs associated with the commercial team and product launch.
• Revaluation Losses: The company recognized a loss of $14.9 million related to the revaluation of contingent consideration and a $5 million loss from warrant remeasurement due to share price appreciation.
• Market Access: Although coverage for Ryoncil is expanding, ongoing efforts are necessary to ensure comprehensive access across all states and payers.

5. Notable Q&A Insights

• Sales Distribution: Initial sales were weighted towards the latter part of the quarter, making it difficult to project future revenue trajectories.
• Gross-to-Net Dynamics: The gross-to-net adjustment is expected to remain stable as the launch progresses.
• Adult GvHD Trial Design: The pivotal trial will include patients on Jakafi, aiming to enhance response rates in severe cases of GvHD.
• Inventory Management: Ryoncil is administered based on patient weight, with ongoing inventory replenishment as treatments are provided.

Overall, Mesoblast is positioned for growth with its FDA-approved products and expanding market opportunities, although it faces challenges related to expenses and the need for continued market access efforts.